Can Aurora Cannabis’ Cost-Cutting Turn Things Around?

: ACB | Aurora Cannabis Inc. News, Ratings, and Charts

ACB – Aurora Cannabis (ACB) recently cut its stake in an Australian cannabis company. ACB is looking to cut costs in the hopes of turning things around. Will this strategy work? Aaron covers the move and how this will affect the company going forward.

Aurora Cannabis (ACB), once a giant and prosperous cannabis company, has faced many challenges in the past couple of years. For example, the amount of high-priced acquisitions it made left billions of dollars of goodwill and has contributed to multiple quarters of hefty losses.

Since reporting its latest quarterly earnings report, which included their largest loss to date ($1.8 billion), the stock has dropped from $7.50 to $4.70. This is a substantial loss for investors.

The company announced this week that they would be unloading their position in the Australian cannabis company Cann Group. ACB took a $28 million impairment charge, but says it still sees the potential for growth in the Australian market.

Michelle Lefler, a spokeswoman for ACB, wrote an email to Marijuana Business Daily stating, “We continue to see growth potential in this important market and will maintain active relationships with key distribution partners to enhance availability of Aurora’s portfolio of leading, high-quality medical cannabis.” She also stated that the company remains focused on key markets including: Canadian medical and recreational, CBD in the United States, and developed international medical markets.

The move to unload its position in Cann Group is striking, as just this past February, ACB listed Australia as one of its “primary market opportunities.” At this point, it’s pretty clear that the company is in dire need of capital and must do everything it can to clean up its balance sheet. The company currently faces multiple class-action lawsuits from shareholders that have hired the firms of Rosen Law, Bragar Eagel & Squire, and Wolf Haldenstein Adler Freeman & Herz LLP for damages due to misleading shareholders.

ACB had an 11.84% stake in Cann group, which accounted for roughly 22.4% of the company’s shares as of June. The sale comes only a few weeks after the company recorded an impairment charge of $37.2 million CAD for its position in the company. This loss is on top of the $18.2 million they lost last year.

As ACB continues to sell off its assets in hopes of profitability, only time will tell if their new CEO’s ambitious plan will work. CEO Miguel Martin stated that he would be focusing on premium cannabis higher-margin products, as opposed to value brands, despite value brands showing stronger sales growth. ACB is a company that has the potential to make a recovery, but this will not happen overnight.

(Disclosure: The author is long ACB)

Want More Great Investing Ideas?

2020 Stock Market Bubble Part 2?

7 Best ETFs for the NEXT Bull Market

5 WINNING Stocks Chart Patterns


ACB shares were trading at $4.62 per share on Wednesday morning, down $0.16 (-3.35%). Year-to-date, ACB has declined -82.18%, versus a 10.27% rise in the benchmark S&P 500 index during the same period.


About the Author: Aaron Missere


Aaron is an experienced investor who is also the CEO of Departures Capital. His primary focus is on the cannabis industry. He also hosts a weekly show on YouTube about marijuana stocks. Learn more about Aaron’s background, along with links to his most recent articles. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
ACBGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Inflation Not Fading Fast Enough for Stock Investors

Investors may have celebrated the end of high inflation too soon. The CPI report shows inflation bouncing higher and thus pushing back the start date for Fed rate cuts. This has the S&P 500 (SPY) coming off recent highs. This begs questions like how much more downside could we see? And when will the bull market get back on track? 44 year investment veteran Steve Reitmeister shares his answers to these questions in this timely commentary including a preview of his top picks to stay ahead of the pack. Read on below for more...

Software Stock Watchlist - Should You Buy, Sell, or Hold?

Rapid growth in the software sector is fueled by increasing digitalization, growing cloud adoption, integration of AI and ML capabilities into software products, and rising cyber threats. So, let’s analyze whether you should buy, hold, or sell software stocks The Sage Group (SGPYY), Qualys (QLYS), and Blackbaud (BLKB). Read more to find out...

Bank of America (BAC) Braces for Earnings - Strategies for Investors

Bank of America (BAC), the second-largest U.S. lender, will publish its first-quarter earnings on April 16. With the bank’s net interest income expected to decline in the first quarter, should investors consider investing in the stock ahead of its earnings? Read on to learn my view...

4 Bullish Airliner Stocks to Consider - Buy or Watch?

The airline industry is well-poised for continued growth thanks to surging passenger and air cargo demand amid rapid urbanization, globalization, and economic expansion. So, should you buy or watch airline stocks SkyWest (SKYW), International Consolidated Airlines (ICAGY), Controladora Vuela (VLRS), and Air Canada (ACDVF)? Read on…

Updated 2024 Stock Market Outlook

The bull market continues to rage on with the S&P 500 (SPY) making new highs. That is the past...the question is what does the future hold? That is why 44 year investment veteran Steve Reitmeister provides this updated 2024 Stock Market Outlook to help you carve a path to outperformance the rest of the year. Read on below for the full story...

Read More Stories

More Aurora Cannabis Inc. (ACB) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All ACB News